The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey
The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey
复制标题
DOI：
10.1016/j.jalz.2014.06.006
复制
发表时间：
2015-02-01
影响因子：
14
通讯作者：
Frisoni, Giovanni B.
中科院分区：
文献类型：
--
作者：
Bocchetta, Martina;Galluzzi, Samantha;Frisoni, Giovanni B.
我们调查了阿尔茨海默病（AD）生物标志物在欧洲阿尔茨海默病联盟中心的使用，并评估了其对轻度认知障碍（MCI）病因诊断的感知有用性。我们调查了脑淀粉样变性（淀粉样蛋白位置发射断层扫描[PET]，脑脊液[CSF] A β 42）和神经变性（MR上的内侧颞叶萎缩[MTA]，氟脱氧葡萄糖正电子发射断层扫描[FDG-PET]，CSF tau）标记物的可用性，使用频率和诊断有用性的信心。最常用的生物标志物是视觉评定的MTA（37名应答者中有75%报告“总是/经常”使用它），其次是CSF标志物（22%）、FDG-PET（16%）和淀粉样蛋白-PET（3%）。只有45%的应答者认为MTA有助于诊断信心，其中贡献被评为“中度”。当淀粉样蛋白和神经元损伤生物标志物均异常时，79%的应答者感到“非常/极其”舒适地提供AD所致MCI的诊断（与任何单个生物标志物相比，P <0.02）。应答者基本上同意淀粉样变性和神经元损伤生物标志物的组合是强烈指示性AD特征。(C)2015年，阿尔茨海默氏症协会。爱思唯尔公司出版All rights reserved.
We investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI). We surveyed availability, frequency of use, and confidence in diagnostic usefulness of markers of brain amyloidosis (amyloid position emission tomography [PET], cerebrospinal fluid [CSF] A beta 42) and neurodegeneration (medial temporal atrophy [MTA] on MR, fluorodeoxyglucose positron emission tomography [FDG-PET], CSF tau). The most frequently used biomarker is visually rated MTA (75% of the 37 responders reported using it "always/frequently") followed by CSF markers (22%), FDG-PET (16%), and amyloid-PET (3%). Only 45% of responders perceive MTA as contributing to diagnostic confidence, where the contribution was rated as "moderate". Seventy-nine percent of responders felt "very/extremely" comfortable delivering a diagnosis of MCI due to AD when both amyloid and neuronal injury biomarkers were abnormal (P < .02 versus any individual biomarker). Responders largely agreed that a combination of amyloidosis and neuronal injury biomarkers was a strongly indicative AD signature. (C) 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.